Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
79,235,030
-
Total 13F shares
-
24,614,198
-
Share change
-
+24,614,198
-
Total reported value
-
$385,431,208
-
Price per share
-
$15.66
-
Number of holders
-
66
-
Value change
-
+$385,431,208
-
Number of buys
-
66
Institutional Holders of Mineralys Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MLYS) as of Q1 2023
As of 31 Mar 2023,
Mineralys Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MLYS) was held by
66 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,614,198 shares.
The largest 10 holders included
Samsara BioCapital, LLC, RA CAPITAL MANAGEMENT, L.P., ADAMS STREET PARTNERS LLC, SR ONE CAPITAL MANAGEMENT, LP, Avidity Partners Management LP, Rock Springs Capital Management LP, RTW INVESTMENTS, LP, BlackRock Inc., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), and Laurion Capital Management LP.
This page lists
66
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.